HC
ITCI

Henshaw Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Henshaw Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,336
Closed -$279K – 306
2024
Q4 		$279K Hold
3,336
– – 0.01% 281
2024
Q3 		$244K Sell
3,336
-5,064
-60% -$381K 0.01% 296
2024
Q2 		$575K Buy
8,400
+156
+2% +$10.8K 0.03% 160
2024
Q1 		$570K Sell
8,244
-1,026
-11% -$70.5K 0.03% 155
2023
Q4 		$664K Buy
9,270
+1,529
+20% +$88K 0.03% 139
2023
Q3 		$403K Buy
+7,741
New +$451K 0.02% 179

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Henshaw Capital's ITCI Position: Q1 2025 in Review

Henshaw Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 3,336 shares — an estimated $279K sold.

Henshaw Capital first reported a position in ITCI in Q3 2023 and held it in 6 quarters. The position peaked at $664K in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Henshaw Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Henshaw Capital sold 3,336 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $279K.
  • Henshaw Capital first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 6 quarters.
  • Henshaw Capital's Intra-Cellular Therapies Inc. position peaked at $664K in Q4 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Henshaw Capital's 13F filing for Q1 2025, filed 28 May 2026.